A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00242359

Enrollment

Registered

2005-10-20

Start date

2005-11-30

Completion date

2009-01-31

Last updated

2019-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy Induced Asthma

Brief summary

Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.

Interventions

DRUGomalizumab

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. ages 18-65 2. occupation that involves close contact with animals 3. stable dose of ICS for 30 days 4. Skin test positive to one or more animals 5. evidence of asthma on spirometry 6. demonstrate PEFR variability-

Exclusion criteria

1. on allergen immunotherapy 2. on prohibited medications 3. unstable asthma 4. recent URI 5. known hypersensitivity to omalizumab-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026